TAUNS Laboratories,Inc. (TYO:197A)

TAUNS Laboratories,Inc. Income Statement

Financials in millions JPY. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023
Period Ending	Jun 30, 2024	Jun 30, 2023
Revenue	18,435	15,673
Revenue Growth (YoY)	17.62%	-
Cost of Revenue	5,937	6,473
Gross Profit	12,498	9,200
Selling, General & Admin	4,045	3,819
Operating Expenses	4,468	4,233
Operating Income	8,030	4,967
Interest Expense	-31.21	-21.81
Interest & Investment Income	7.69	7.47
Other Non Operating Income (Expenses)	-165.95	0.51
EBT Excluding Unusual Items	7,841	4,953
Gain (Loss) on Sale of Investments	-1.67	-297.85
Gain (Loss) on Sale of Assets	-6.16	-0.74
Other Unusual Items	1.89	-
Pretax Income	7,835	4,655
Income Tax Expense	2,061	1,620
Net Income	5,774	3,035
Net Income to Common	5,774	3,035
Net Income Growth	90.26%	-
Shares Outstanding (Basic)	100	100
Shares Outstanding (Diluted)	107	100
Shares Change (YoY)	6.94%	-
EPS (Basic)	57.74	30.35
EPS (Diluted)	53.99	30.35
EPS Growth	77.90%	-
Free Cash Flow	6,182	-4,247
Free Cash Flow Per Share	57.80	-42.47
Dividend Per Share	10.650	-
Gross Margin	67.80%	58.70%
Operating Margin	43.56%	31.69%
Profit Margin	31.32%	19.36%
Free Cash Flow Margin	33.53%	-27.10%
EBITDA	8,706	5,607
EBITDA Margin	47.23%	35.78%
D&A For EBITDA	676.16	639.97
EBIT	8,030	4,967
EBIT Margin	43.56%	31.69%
Effective Tax Rate	26.30%	34.80%

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.